| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,523,305 | 2,389,801 | ||
| General and administrative | 2,327,391 | 3,647,728 | ||
| Total operating expenses | 4,850,696 | 6,037,529 | ||
| Loss from operations | -4,850,696 | -6,037,529 | ||
| Gain (loss) on valuation of warrants | -294,276 | -501,598 | ||
| Interest income | 112,543 | 88,020 | ||
| Total other income (expense) | 406,819 | 589,618 | ||
| Net loss | -4,443,877 | -5,447,911 | ||
| Earnings per share, basic | -1.41 | -3.39 | ||
| Earnings per share, diluted | -1.41 | -3.39 | ||
| Weighted average number of shares outstanding, basic | 3,162,040 | 1,608,799 | ||
| Weighted average number of shares outstanding, diluted | 3,162,040 | 1,608,799 | ||
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)